Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 51,884 shares at $48.81 ($2.5M) on 2025-08-20, disclosed to the SEC on 2025-08-22.
Scheduled sale ($2.5M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $48.81 | 25,728 | $1.3M | 49.6% |
| 2 | $48.81 | 25,728 | $1.3M | 49.6% |
| 3 | $49.25 | 428 | $21K | 0.8% |
| Total | $48.81 avg | 51,884 | $2.5M | 100% |
| Filing → |
| BBIO | SELL | 2026-06-08 | $4.6M | — | Filing → |
| BBIO | SELL | 2026-05-26 | $1.8M | — | Filing → |
| BBIO | SELL | 2026-05-11 | $5.3M | — | Filing → |